Enhanced Real‐Time Monitoring of Catalytic Therapy Efficacy with Dual‐Channel MRI and Fluorescent Platform

Abstract Catalytic therapies, such as chemodynamic therapy and ferroptosis, harness the tumor microenvironment to enhance the specificity and penetration of treatments, thus improving targeted tumor therapy. Despite these advancements, treatment effectiveness varies due to individual differences, making precise monitoring of drug activity and dosage essential to optimize therapy. Traditional imaging strategies, which monitor metal ion release or reactive oxygen species production, frequently fail to well correlate with therapeutic outcome. Herein, this study have developed an integrated self‐monitoring catalytic therapy platform that combines palladium‐ and manganese‐based nanoparticles (PdMn NPs) with caspase‐3 activated probe (Casp probe). Dual‐channel MRI and fluorescent probe, responsive to both low pH and caspase‐3 activity, significantly enhances the accuracy of real‐time therapeutic evaluations, allowing for early reporting treatment response (in 6 h), earlier than tumor volume reduction (8 days). This approach improves the assessment of therapeutic outcomes and aligns with the shift toward individualized cancer treatment protocols.